- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| THARIMMUNE Aktie jetzt für 0€ handeln | |||||
| Do | Tharimmune, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| Mi | Tharimmune expands IP portfolio for opioid countermeasure technology | 3 | Investing.com | ||
| Mi | Tharimmune Inc.: Tharimmune Secures Key Global Patents for TH-104, Laying Foundation for Broader Indications Following Initial Development as a National Security Medical Countermeasure Against Weaponized Fentanyl | 228 | ACCESS Newswire | RED BANK, NEW JERSEY / ACCESS Newswire / August 13, 2025 / Tharimmune, Inc. (Nasdaq:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company dedicated to developing innovative therapeutic... ► Artikel lesen | |
| 07.08. | Tharimmune, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 05.08. | Tharimmune Inc.: Nancy Davis, Visionary Philanthropist and Founder of Race to Erase MS and Cure Addiction Now Appointed to the Tharimmune Board of Directors | 125 | ACCESS Newswire | RED BANK, NJ / ACCESS Newswire / August 5, 2025 / Tharimmune, Inc. (NASDAQ:THAR), ("Tharimmune" or the "Company), a clinical-stage biotechnology company dedicated to developing innovative therapeutic... ► Artikel lesen | |
| 04.08. | Tharimmune Inc.: Tharimmune Issues Comprehensive Corporate Update including Lead TH104 as Critical National Security Solution Against Weaponized Fentanyl and TH023 Poised to Revolutionize Oral Antibody Delivery | 152 | ACCESS Newswire | -Company closes approximately $5.47 million in equity financing in 2Q/3Q25-TH104 potentially fills a critical National Security Need against Weaponized Fentanyl-TH023 may fulfill the promise of delivering... ► Artikel lesen | |
| 28.07. | Tharimmune, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 24.07. | Tharimmune prices $1.74 million direct offering | 1 | Seeking Alpha | ||
| 24.07. | Tharimmune Inc.: Tharimmune Announces Pricing of $1.74 Million Registered Direct Public Offering of Common Stock and Warrants | 367 | ACCESS Newswire | RED BANK, NJ / ACCESS Newswire / July 23, 2025 / Tharimmune, Inc. (the "Company" and "Tharimmune") (Nasdaq Capital Market:THAR), a clinical-stage biotechnology company committed to pioneering therapies... ► Artikel lesen | |
| 11.07. | Tharimmune, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 20.06. | Tharimmune, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 17.06. | Tharimmune announces key leadership changes to advance pipeline | 2 | Investing.com | ||
| 17.06. | Tharimmune Inc.: Tharimmune Announces Key Leadership Appointments Including James Gordon Liddy Joining Board of Directors | 272 | ACCESS Newswire | BRIDGEWATER, NEW JERSEY / ACCESS Newswire / June 17, 2025 / Tharimmune, Inc. (NASDAQ:THAR), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for inflammation and... ► Artikel lesen | |
| 10.06. | Tharimmune, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 19.05. | Tharimmune Inc.: Tharimmune Appoints Renowned Counter-Terrorism and Critical Infrastructure Expert James Gordon Liddy ) as Key Strategic Advisor Against Weaponized Fentanyl and Other High-Potency Opioids Following Positive FDA Feedback | 265 | ACCESS Newswire | BRIDGEWATER, NJ / ACCESS Newswire / May 19, 2025 / Tharimmune, Inc. (Nasdaq:THAR), a clinical-stage biopharmaceutical company focused on developing innovative therapeutics, today announced the appointment... ► Artikel lesen | |
| 12.05. | Tharimmune, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 09.05. | Tharimmune, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 06.05. | Tharimmune macht Fortschritte bei Opioid-Prophylaxe-Medikament TH104 | 1 | Investing.com Deutsch | ||
| 06.05. | Tharimmune Inc.: Tharimmune Presents Positive Clinical Data Highlighting TH104 Metabolic Profile and Advances Program for Prophylaxis Against Ultrapotent Opioid Exposure Following FDA Feedback | 204 | ACCESS Newswire | BRIDGEWATER, NEW JERSEY / ACCESS Newswire / May 6, 2025 / Tharimmune, Inc., (Nasdaq:THAR) ("Tharimmune" or the "Company") a clinical-stage biopharmaceutical company focused on developing innovative... ► Artikel lesen | |
| 01.05. | Tharimmune Inc.: Tharimmune Abstracts Accepted for Presentation at Upcoming DDW and EASL Conferences | 242 | ACCESS Newswire | BRIDGEWATER, NJ / ACCESS Newswire / May 1, 2025 / Tharimmune, Inc., (Nasdaq:THAR) ("Tharimmune" or the "Company") a clinical-stage biopharmaceutical company focused on developing innovative therapeutics... ► Artikel lesen |
1 2 3 Weiter >>
45 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 97,00 | -0,05 % | Pharma und Biotech News bei Eli Lilly, NetraMark, BioNTech und Curevac | Der neue US-Gesundheitsminister Robert F. Kennedy setzt nach und nach mehr Akzente in der US-amerikanischen Gesundheitspolitik. Zuletzt verbot der Gesundheitsminister den Einsatz der Quecksilberverbindung... ► Artikel lesen | |
| CUREVAC | 4,664 | -0,51 % | CureVac im Rampenlicht: Warum der Montag alles verändern könnte!!! | ||
| AMGEN | 253,05 | -0,16 % | SA analyst upgrades/downgrades: COHR, AMGN, KKR, SOFI | ||
| NOVAVAX | 8,157 | -0,32 % | Novavax Aktie: Platzt am Montag die Bombe? Diese Neuigkeiten müssen Anleger dringend beachten! | ||
| BIOGEN | 118,30 | -0,17 % | Biogen Inc.: Biogen and Stoke Therapeutics Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome | - Global, pivotal Phase 3 study will evaluate efficacy and safety of zorevunersen compared to sham over a 52-week treatment period -
- Dravet syndrome is a rare genetic disease characterized by... ► Artikel lesen | |
| MAINZ BIOMED | 1,820 | +7,69 % | EQS-News: Mainz BioMed N.V.: Mainz Biomed erhält Zulassung für die Vermarktung von ColoAlert® in der Schweiz | Emittent / Herausgeber: Mainz BioMed N.V.
/ Schlagwort(e): Zulassungsgenehmigung
Mainz Biomed erhält Zulassung für die Vermarktung von ColoAlert® in der Schweiz
13.08.2025... ► Artikel lesen | |
| VIKING THERAPEUTICS | 34,815 | +1,77 % | The 3 Things That Matter for Viking Therapeutics Now | ||
| INTELLIA THERAPEUTICS | 9,464 | +0,72 % | Intellia Therapeutics stock price target slashed by Guggenheim to $14 | ||
| GENMAB | 199,00 | +0,13 % | Genmab A/S stock price target raised to $36 from $35 at H.C. Wainwright | ||
| TEMPUS AI | 63,00 | -0,79 % | Tempus AI's Strong Q2 Fuels Growth Story-More Upside Ahead? | ||
| BIOCRYST PHARMACEUTICALS | 7,374 | +3,16 % | BioCryst Pharmaceuticals, Inc.: BioCryst Announces Departure of Dr. Helen Thackray | RESEARCH TRIANGLE PARK, N.C., Aug. 11, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that Dr. Helen Thackray, chief research and development officer, will... ► Artikel lesen | |
| SAREPTA THERAPEUTICS | 18,695 | +0,21 % | Sarepta sells Arrowhead shares as partnership, debt payments loom | ||
| CARDIOL THERAPEUTICS | 1,118 | +0,18 % | Original-Research: Cardiol Therapeutics Inc (von First Berlin Equity Research GmbH): BUY | Original-Research: Cardiol Therapeutics Inc - from First Berlin Equity Research GmbH
12.08.2025 / 13:31 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group.
The... ► Artikel lesen | |
| EXELIXIS | 32,750 | 0,00 % | Exelixis Q2 2025: Cabozantinib-Franchise wächst um 19 % im Jahresvergleich | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,080 | -3,17 % | PacBio Board Independent Investigation Concludes Allegations Unsubstantiated | MENLO PARK, Calif., May 12, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced that the Special Committee of its Board of Directors (the "Special Committee") has concluded its independent... ► Artikel lesen |
THARIMMUNE INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 1,310 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu THARIMMUNE INC finden Sie auf Wallstreet Online.